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Background
Cyclic GMP is a crucial second messenger that translates
extracellular signals into a variety of cellular responses.
As a central mediator of the Nitric Oxide-cGMP signal-
ling cascade, which regulates vascular tone, platelet
aggregation, nociception and hipocampal/cerebellar
learning, Cyclic GMP-dependent protein kinases (PKGs)
represents an important drug target for treating hyper-
tensive diseases and erectile dysfunction.
The fidelity of the NO-cGMP signalling pathway is lar-
gely dependent on PKG’s ability to selectively bind
cGMP over cAMP. Although both cGMP and cAMP
bind and activate PKG, cGMP preferentially activates
PKG 60-100 fold better than cAMP; yet, little is known
about the molecular features required for the cGMP
selectivity of PKG. We have investigated the mechanism
of cyclic nucleotide binding to PKG by determining crys-
tal structures of the amino-terminal cyclic nucleotide-
binding domain (CNBD-A) of human PKG I bound to
either cGMP or cAMP. We also determined the structure
of CNBD-A in the absence of bound nucleotide.
Results
The crystal structures of CNBD-A with bound cAMP or
cGMP reveal that cAMP binds in either syn or anti con-
figurations whereas cGMP binds only in a syn configura-
tion, with a conserved threonine residue anchoring both
cyclic phosphate and guanine moieties. The structure of
CNBD-A in the absence of bound cyclic nucleotide was
similar to that of the cyclic nucleotide bound structures.
Surprisingly, isothermal titration calorimetry experi-
ments demonstrated that CNBD-A binds both cGMP
and cAMP with a relatively high affinity, showing an
approximately two-fold preference for cGMP.
Overall structure of the PKG Ib CNBD-A:cGMP com-
plex showing on the left, the PKG Ib CGBD-A:cAMP
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Table 1 Data and refinement statistics
Data set cGMP bound cAMP bound Partial APO
Space group P6222 P6222 P43
Cell constants (Å) a=b=107,
c=171
a=b=90.0,
g=120
a=b=107,
c=169
a=b=90.0,
g=120
a=b=62.6,
c=202
a=b=g=90.0
Wavelength (Å) 1.0 1.0 1.0
Resolution (Å) 50 – 2.9 50 – 2.49 45-2.75
Total/unique
reflections
402498/13503 293611/20607 80424/19782
Average redundancy 29.8(20.2) 13.8(14.2) 4.1(4.1)
Completeness (%) 100(100) 98.7(99.6) 100(99.6)
<I>/<sI> 21.2(2.10) 43.5(5.62) 31.2 (2.39)
Rsym
◊ (%) 13.5(n/a) 10.1(42.4) 5.9(46.4)
Rwork (%) 20.4 20.6 18.0
Rfree
¶ (%) 26.0 23.0 25.1
Overall B value( Å
2) 73.4 46.6 94.4
Rmsd bond length
(Å)
0.010 0.014 0.005
Rmsd bond angle(°) 1.42 1.274 0.942
◊Rsym = ∑h∑i|I(h)-I(h)i|I∑h∑iI(h)i, where I(h) is the mean intensity after rejections.
§Numbers in parentheses correspond to the highest resolution shell of data,
which were 2.98 to 2.90 for the cGMP, 2.53 to 2.49 Å for the cAMP and 2.85
to 2.75Å for APO.
||Rwork = ∑h||Fobs(h)| -|Fcalc(h)||I∑h|Fobs(h)|; no I/s cutoff was used during
refinement.
¶ 5.0% of the observed intensities was excluded from refinement for cross
validation purposes.
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any medium, provided the original work is properly cited.complex in the middle, and the partial apo on the right.
All three crystals contained more than one molecule per
unit cell, which enable us to sample different modes of
interaction with cyclic nucleotides. The phosphate bind-
ing cassette (PBC) is shown in yellow, the aBh e l i xi n
red and N- and C-termini are labeled. For the cGMP
and cAMP complexes, bound cyclic nucleotides are
shown with the Fo-Fc omit map electron density.
Cyclic Nucleotides interacting with the cGMP pocket.
Both cGMP and cAMP bond in the cGMP binding pocket
are shown on the far left and right and their Isothermal
titration calorimetry data binding to the PKG Ib CNBD-A
shown in the middle. The cGMP-binding site is marked
with three different sites: the short P-helix together with
conserved glutamate and arginine residues at the PBC
which captures the sugar phosphate (Site 1); a key residue,
Thr
193 at the end of PBC that bridges the cyclic phosphate
to the guanine ring (Site 2); and the b5-strand that pro-
vides a unique docking site for the guanine ring (Site 3).
Unlike cGMP, cAMP binds in two different configura-
tions, anti in one molecule (shown on the far right panel)
and syn in the other with different sets of contacts.
Although the sugar phosphates share the same set of con-
tacts with the protein at site 1, each purine ring of cAMP
shows different contacts with the protein at sites 2 and
3The calorimetric measurements for cAMP and of cGMP
binding to PKG Ib (92-227) were carried out using a VP-
ITC calorimeter (MicroCal LLC, Northampton, MA).
Conclusion
Our findings suggest that CNBD-A binds cGMP in the
syn conformation through its interaction with Thr193
and an unusual cis-peptide forming residues Leu172 and
Cys173. Although these studies provide the first struc-
tural insights into cyclic nucleotide binding to PKG, our
ITC results show only a two-fold preference for cGMP,
indicating that other domains are required for the pre-
viously reported cyclic nucleotide selectivity.
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